Tesamorelin telehealth cost: what providers charge and how to evaluate a quote
Tesamorelin is a GHRH analogue and — importantly — one of the few peptides in this category that is <b>genuinely FDA-approved</b>, though for a narrow indication: the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is marketed as Egrifta. Everything else it is sold for is off-label.
What telehealth providers charge
Publishing an unverified number would be worse than publishing none. When we have captured them, they will appear here with a source and a verification date, exactly like our GLP-1 pricing.
Normalise any quote before you compare it
Because we will not hand you a number we cannot stand behind, the useful thing we can give you is the method — the same one we apply to GLP-1 pricing, where we do hold verified figures.
| Ask for… | Because… |
|---|---|
| The total monthly cost, every fee included | Split billing — medication plus a membership — is the commonest way a price looks lower than it is |
| The ongoing price, not the first month | Introductory rates are customer-acquisition pricing. You pay the ongoing rate eleven months of twelve |
| Whether the price rises with dose | A programme cheapest at the starting dose can be the most expensive at maintenance |
| What happens if you cancel early | On a committed plan this is the question most likely to cost you money |
| Whether labs and shipping are included | 'All-inclusive' is used loosely. Test it against specifics |
| The annual total | Monthly figures are how this is marketed; annual totals are how it is lived |
Frequently asked questions
What does Tesamorelin cost through telehealth?
We have not verified a market price. On October 15, 2026, the Egrifta WR website published no list price, describing co-pay and patient assistance programs instead, and Oak Longevity priced tesamorelin only after an assessment. Ask for the total cost in writing, and ask whether you will get Egrifta WR or a compounded product.
Is Tesamorelin FDA-approved?
Yes, for one use. Egrifta WR is approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy, and its label says it is not indicated for weight-loss management. Compounded tesamorelin is not the approved product, and other uses are off-label.
Does Tesamorelin work?
FDA approved Egrifta WR on clinical trial evidence in adults with HIV and lipodystrophy. We found no comparable trials for general fat loss, anti-ageing or performance in other people, and approval for one condition is not evidence for another.
Sources
- U.S. Food and Drug Administration — approved labels and compounding guidance for this molecule.
- PubMed / NIH — indexed human clinical literature.
- ClinicalTrials.gov — registered trials, where they exist.
- Our source hierarchy and pricing-verification methodology.